Literature DB >> 9369188

Presence of functional luteinizing hormone/chorionic gonadotropin (hCG) receptors in human breast cell lines: implications supporting the premise that hCG protects women against breast cancer.

S Lojun1, S Bao, Z M Lei, C V Rao.   

Abstract

We investigated MCF-7 and MDA-MB-231 human breast cancer cell lines and immortalized mammary epithelial HBL-100 cells for the presence of functional LH/hCG receptors. The results revealed that all three breast cell lines contain LH/hCG receptor mRNA transcripts and receptor proteins that can bind 125I-hCG. The MCF-7 cells, however, contain higher levels than the others. Culturing MCF-7 cells with highly purified hCG resulted in a dose- and time-dependent significant decrease in steady-state estradiol receptor mRNA and protein levels as compared to controls, with the maximal decrease occurring after 4 h of culture with 10 ng/ml hCG. The studies on cell growth demonstrated that hCG treatment in the presence of minimal or no fetal bovine serum had a time-dependent significant inhibitory effect on MCF-7 and HBL-100, but not on MDA-MB-231 cells. In summary, our results demonstrate that human breast cell lines contain functional LH/hCG receptors. The hCG effects in MCF-7 cells are consistent with a premise that hCG protects women against breast cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9369188     DOI: 10.1095/biolreprod57.5.1202

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  9 in total

1.  Expression and characterization of recombinant beta-subunit hCG homodimer.

Authors:  L Lobel; S Pollak; S Wang; M Chaney; J W Lustbader
Journal:  Endocrine       Date:  1999-06       Impact factor: 3.633

2.  The protective effect of parity in hormone receptor-positive, Ki-67 expressing breast cancer.

Authors:  Se Kyung Lee; Seok Won Kim; Sang-Ah Han; Won Ho Kil; Jeong Eon Lee; Seok Jin Nam
Journal:  World J Surg       Date:  2014-05       Impact factor: 3.352

3.  Effect of infertility treatment and pregnancy-related hormones on breast cell proliferation in vitro.

Authors:  Anne Cooley; Laura Matthews; Stanislav Zelivianski; Ashley Hardy; Jacqueline S Jeruss
Journal:  Hum Reprod       Date:  2011-11-10       Impact factor: 6.918

4.  The LH/hCG Axis in Endometrial Cancer: A New Target in the Treatment of Recurrent or Metastatic Disease.

Authors:  A Arcangeli; I Noci; A Fortunato; G F Scarselli
Journal:  Obstet Gynecol Int       Date:  2010-07-15

5.  LH receptor gene expression is essentially absent in breast tumor tissue: implications for treatment.

Authors:  T Martijn Kuijper; Kirsten Ruigrok-Ritstier; Miriam Verhoef-Post; Djura Piersma; Martijn W P Bruysters; Els M J J Berns; Axel P N Themmen
Journal:  Mol Cell Endocrinol       Date:  2009-01-20       Impact factor: 4.102

6.  Human chorionic gonadotropin (hCG) prevents the transformed phenotypes induced by 17 beta-estradiol in human breast epithelial cells.

Authors:  Hilal Kocdor; Mehmet A Kocdor; Jose Russo; Kara E Snider; Johana E Vanegas; Irma H Russo; Sandra V Fernandez
Journal:  Cell Biol Int       Date:  2009-07-30       Impact factor: 3.612

7.  Magnetic Gold Nanoshells: Step-wise Changing of Magnetism through Step-wise Biofunctionalization.

Authors:  Challa S S R Kumar; Faruq Mohammad
Journal:  J Phys Chem Lett       Date:  2010-10-21       Impact factor: 6.475

8.  Beta-hCG/LH receptor (b-HCG/LH-R) expression is increased in invasive versus preinvasive breast cancer: implications for breast carcinogenesis?

Authors:  Gernot Hudelist; Pia Wuelfing; Klaus Czerwenka; Martin Knöfler; Sandra Haider; Anneliese Fink-Retter; Daphne Gschwantler-Kaulich; Georg Pfeiler; Ernst Kubista; Christian F Singer
Journal:  J Cancer Res Clin Oncol       Date:  2008-08-29       Impact factor: 4.553

Review 9.  Participation of signaling pathways in the derepression of luteinizing hormone receptor transcription.

Authors:  Maria L Dufau; Mingjuan Liao; Ying Zhang
Journal:  Mol Cell Endocrinol       Date:  2009-05-21       Impact factor: 4.102

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.